Corcept Therapeutics Incorporated (CORT) shares are trading at higher $19.87 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $16.75.
To add more color to this target, the company’s high over the last year is $18.52 and the low is $9.70. Over the last 52 weeks, CORT is up 60.24% while the S&P 500 is up 21.65%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, CORT reported a profit of $87.33 million. Corcept Therapeutics Incorporated also saw revenues increase to $88.56 million. In addition, CORT has free cash flow of $86.37 million as of 06-2020. The company’s EBITDA came in at $35.77 million which compares well with its peers.
FREE CONFIDENTIAL REPORT
3 Stocks Set To Soar By January 1st, 2021
You have Successfully Subscribed!
CORT booked profit margins of 32.50%, its Return on Equity (ROE) is 29.10%, and its Return on Assets is 26.50%. All told, it is clear that, CORT needs to be on your watchlist.
Find out when CORT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. CORT has a short ratio of 21.92 and outstanding shares of 115.01M.
CORT has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.74 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at 0.93. Corcept Therapeutics Incorporated CORT also noted assets of $497.82 million at the end of the last quarter. Investors should also keep an eye on sector updates as CORT has historically followed its peers on positive news.
All told, Corcept Therapeutics Incorporated CORT has strung together solid data and demonstrated underlying fundamentals. At its current valuation, CORT represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Corcept Therapeutics Incorporated CORT is now commanding a market cap of 2.27B and a float of 104.24M. CORT is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of CORT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in CORT, either long or short, and we have not been compensated for this article.